Literature DB >> 30339852

Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease.

Katherine N Cahill1, Katherine Murphy2, Joseph Singer2, Elliot Israel3, Joshua A Boyce1, Tanya M Laidlaw4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30339852      PMCID： PMC6519056          DOI： 10.1016/j.jaci.2018.10.007

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  8 in total

1.  Tryptase and histamine release during aspirin-induced respiratory reactions.

Authors:  J V Bosso; L B Schwartz; D D Stevenson
Journal:  J Allergy Clin Immunol       Date:  1991-12       Impact factor: 10.793

2.  Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics.

Authors:  D D Stevenson; R A Simon; D A Mathison; S C Christiansen
Journal:  Ann Allergy Asthma Immunol       Date:  2000-12       Impact factor: 6.347

3.  Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis.

Authors:  L B Schwartz; T R Bradford; C Rouse; A M Irani; G Rasp; J K Van der Zwan; P W Van der Linden
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

4.  Type 2 Cysteinyl Leukotriene Receptors Drive IL-33-Dependent Type 2 Immunopathology and Aspirin Sensitivity.

Authors:  Tao Liu; Nora A Barrett; Yoshihide Kanaoka; Eri Yoshimoto; Denise Garofalo; Haley Cirka; Chunli Feng; Joshua A Boyce
Journal:  J Immunol       Date:  2017-12-27       Impact factor: 5.422

5.  Effect of leukotriene modifier drugs on the safety of oral aspirin challenges.

Authors:  Andrew White; Elizabeth Ludington; Purvi Mehra; Donald D Stevenson; Ronald A Simon
Journal:  Ann Allergy Asthma Immunol       Date:  2006-11       Impact factor: 6.347

6.  Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.

Authors:  Katherine N Cahill; Jillian C Bensko; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2014-09-11       Impact factor: 10.793

7.  Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.

Authors:  A R Fischer; M A Rosenberg; C M Lilly; J C Callery; P Rubin; J Cohn; M V White; Y Igarashi; M A Kaliner; J M Drazen
Journal:  J Allergy Clin Immunol       Date:  1994-12       Impact factor: 10.793

8.  A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease.

Authors:  Tanya M Laidlaw; Katherine N Cahill; Juan Carlos Cardet; Katherine Murphy; Jing Cui; Brittney Dioneda; Parul Kothari; Benjamin A Raby; Elliot Israel; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2018-06-08       Impact factor: 10.793
  8 in total
  8 in total

1.  Mediator production and severity of aspirin-induced respiratory reactions: Impact of sampling site and body mass index.

Authors:  Katherine N Cahill; Pingsheng Wu; Ginger L Milne; Taneem Amin; Joseph Singer; Katherine Murphy; Erin Lewis; Deborah Gapko; Joshua A Boyce; Katherine M Buchheit; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2022-01-11       Impact factor: 14.290

Review 2.  NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets.

Authors:  Tanya M Laidlaw; Joshua M Levy
Journal:  Curr Allergy Asthma Rep       Date:  2020-03-14       Impact factor: 4.806

Review 3.  Aspirin sensitivity: Lessons in the regulation (and dysregulation) of mast cell function.

Authors:  Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2019-10       Impact factor: 10.793

Review 4.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

5.  Scoring tool for systemic symptoms during aspirin challenge detects mediator production in aspirin-exacerbated respiratory disease.

Authors:  Patrick J Staso; Pingsheng Wu; Tanya M Laidlaw; Katherine N Cahill
Journal:  Ann Allergy Asthma Immunol       Date:  2021-03-27       Impact factor: 6.248

6.  NSAID-exacerbated respiratory disease: a population study.

Authors:  Heidi Andersén; Pinja Ilmarinen; Jasmin Honkamäki; Leena E Tuomisto; Hanna Hisinger-Mölkänen; Helena Backman; Bo Lundbäck; Eva Rönmark; Tari Haahtela; Anssi Sovijärvi; Lauri Lehtimäki; Päivi Piirilä; Hannu Kankaanranta
Journal:  ERJ Open Res       Date:  2022-01-24

Review 7.  Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease.

Authors:  Hyo-In Rhyou; Young-Hee Nam; Hae-Sim Park
Journal:  Allergy Asthma Immunol Res       Date:  2022-03       Impact factor: 5.764

Review 8.  Lipid-mediated innate lymphoid cell recruitment and activation in aspirin-exacerbated respiratory disease.

Authors:  Kellen J Cavagnero; Taylor A Doherty
Journal:  Ann Allergy Asthma Immunol       Date:  2020-09-17       Impact factor: 6.347
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.